Table 3.
Overall survival and treatment outcomes
|
AKT1 mutant, n=153, N (%) |
AKT1 wildtype, n=302 N (%) |
p | |
|---|---|---|---|
| Unadjusted Overall Survival | |||
| Median, months (95% CI) | 64.6(48.8–95.7) | 52.3(46.4–61.6) | .33 |
| 5-year survival rate, % (95% CI) | 53 (43–63) | 45 (38–52) | |
| Adjusted Overall Survival*, months (95% CI) | |||
| Median, months (95% CI) | 24.1 (11.4–35) | 29.9(25.4–33.8) | .97 |
| 5-year survival rate, % (95% CI) | 20 (11–31) | 18 (12–24) | |
| 1st Line^, median DOT, months (95% CI) | |||
| Endocrine Therapy (n=289) | 13(8.2–15.3) | 9.4(7.9–11) | |
| Fulvestrant (n=65) | 13.2(3.6–16.2) | 9.3 (6–12.9) | |
| Chemotherapy (n=135) | 3.9 (3–4.6) | 4.1(3.1–4.7) | |
| 2nd Line^, median DOT, months (95% CI) | |||
| Endocrine Therapy (n=219) | 6 (5–9) | 5.3(4.1–7.3) | |
| Fulvestrant (n=84) | 4 (3–8.4) | 4.6(3.7–5.5) | |
| Chemotherapy (n=137) | 4.2(2.5–5) | 4.1(3.2–4.8) | |
| Received in any treatment line after metastatic diagnosis, median DOT, months (95% CI) | |||
| CDK4/6 inhibitor (n=131) | 5.3 (4–6.2) | 5.3(3.4–8.1) | |
| mTOR inhibitor (n=145)§ | 7.8(4.3–9) | 4.5(3.5–5.3) | |
| Fulvestrant (n=237)§ | 5.8 (4–8.4) | 4.8 (4–5.8) |
*
Applying left-truncation technique, see Methods for details.
^
Refers only to treatment given after metastatic diagnosis;
§
p<0.05; DOT, Duration on treatment.